… in patients with type 2 diabetes with chronic kidney disease. … kidney function in persons
with kidney diseases due to causes other than type 2 diabetes. We designed the Dapagliflozin …

… dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure (HF). …
, end-stage kidney disease, or death from kidney cause was similar in these 2 patient groups: …

… Dapagliflozin is a selective inhibitor of sodium glucose co-… safety of dapagliflozin 10 mg vs
placebo in patients with type 2 … 59 mL/min/1.73 m 2 ; chronic kidney disease [CKD] stage 3A). …

… of dapagliflozin on the prespecified kidney and cardiovascular outcomes in patients with
chronic kidney disease … of cardiovascular disease, in the DAPA-CKD trial (Dapagliflozin and …

… In this prespecified subgroup analysis of the DAPA-CKD trial, we show beneficial effects
of dapagliflozin on kidney and cardiovascular end points in patients with stage 4 CKD at …

… in patients with chronic kidney disease. We aimed to investigate the effects of dapagliflozin
on kidney, … to underlying cause of chronic kidney disease, reported as diabetic nephropathy, …

… Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with
… In this pre-specified analysis, we assessed the effect of dapagliflozin on the rate of change …

… kidney effects of the SGLT2 inhibitor dapagliflozin in patients with proteinuric kidney disease
… on proteinuria in patients with non-diabetic chronic kidney disease and residual proteinuria. …

… patients with or without type 2 diabetes and may explain the protective effects of dapagliflozin
in chronic kidney disease result… Our data indicate that the effects of dapagliflozin on all the …

… disease. Here we report analyses of renal outcomes with the SGLT2 inhibitor dapagliflozin
in the DECLARE–TIMI 58 cardiovascular outcomes trial, which included patients with type 2 …